TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
2016 · Molecular Psychiatry · 116 citations
https://doi.org/10.1038/mp.2016.6
D
Drew Neavin
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
58
Papers
1.6K
Citations
19
h-index
26
i10-index
Drew Neavin is an academic researcher from Garvan Institute of Medical Research. The author has contributed to research in topics: Pluripotent Stem Cells Research & Single-cell and spatial transcriptomics & Tryptophan and brain disorders. The author has an h-index of 19, co-authored 50 publications.
ORCID: 0000-0002-1783-6491Papers by this author
worksMetabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
2019 · Translational Psychiatry · 81 citations
https://doi.org/10.1038/s41398-019-0507-5
Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
2018 · Translational Psychiatry · 76 citations
https://doi.org/10.1038/s41398-017-0056-8
A village in a dish model system for population-scale hiPSC studies
2023 · Nature Communications · 56 citations
https://doi.org/10.1038/s41467-023-38704-1
Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes
2019 · Journal of Affective Disorders · 55 citations
https://doi.org/10.1016/j.jad.2019.11.122
Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings
2021 · Neuropsychopharmacology · 29 citations
https://doi.org/10.1038/s41386-020-00943-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat